Literature DB >> 29167175

Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma.

W Robert Liu1, Margaret A Shipp1.   

Abstract

Classical Hodgkin lymphoma (cHL) is an unusual B-cell-derived malignancy in which rare malignant Hodgkin and Reed-Sternberg (HRS) cells are surrounded by an extensive but ineffective inflammatory/immune cell infiltrate. This striking feature suggests that malignant HRS cells escape immunosurveillance and interact with immune cells in the cancer microenvironment for survival and growth. We previously found that cHLs have a genetic basis for immune evasion: near-uniform copy number alterations of chromosome 9p24.1 and the associated PD-1 ligand loci, CD274/PD-L1 and PDCD1LG2/PD-L2, and copy number-dependent increased expression of these ligands. HRS cells expressing PD-1 ligands are thought to engage PD-1 receptor-positive immune effectors in the tumor microenvironment and induce PD-1 signaling and associated immune evasion. The genetic bases of enhanced PD-1 signaling in cHL make these tumors uniquely sensitive to PD-1 blockade.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29167175      PMCID: PMC5701523          DOI: 10.1182/blood-2017-06-781989

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  60 in total

1.  Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.

Authors:  S Joos; M Küpper; S Ohl; F von Bonin; G Mechtersheimer; M Bentz; P Marynen; P Möller; M Pfreundschuh; L Trümper; P Lichter
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

2.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

3.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

4.  Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Robert A Redd; Geraldine S Pinkus; Yasodha Natkunam; Azra H Ligon; Courtney F Connelly; Christine J Pak; Christopher D Carey; Sarah E Daadi; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Margaret A Shipp; Scott J Rodig
Journal:  Cancer Immunol Res       Date:  2016-10-13       Impact factor: 11.151

5.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

Review 6.  The role of cytokines in classical Hodgkin lymphoma.

Authors:  Brian F Skinnider; Tak W Mak
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

7.  T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition.

Authors:  Enfu Hui; Jeanne Cheung; Jing Zhu; Xiaolei Su; Marcus J Taylor; Heidi A Wallweber; Dibyendu K Sasmal; Jun Huang; Jeong M Kim; Ira Mellman; Ronald D Vale
Journal:  Science       Date:  2017-03-09       Impact factor: 47.728

8.  Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2.

Authors:  Tadashi Yokosuka; Masako Takamatsu; Wakana Kobayashi-Imanishi; Akiko Hashimoto-Tane; Miyuki Azuma; Takashi Saito
Journal:  J Exp Med       Date:  2012-05-28       Impact factor: 14.307

9.  Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

Authors:  Christopher D Carey; Daniel Gusenleitner; Mikel Lipschitz; Margaretha G M Roemer; Edward C Stack; Evisa Gjini; Xihao Hu; Robert Redd; Gordon J Freeman; Donna Neuberg; F Stephen Hodi; Xiaole Shirley Liu; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2017-09-11       Impact factor: 22.113

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316

View more
  16 in total

Review 1.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

2.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

3.  Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma.

Authors:  O Jimenez; S Colli; M Garcia Lombardi; M V Preciado; E De Matteo; P Chabay
Journal:  Cancer Immunol Immunother       Date:  2020-11-12       Impact factor: 6.968

Review 4.  Biochemical Aspects of PD-L1 Regulation in Cancer Immunotherapy.

Authors:  Jinfang Zhang; Fabin Dang; Junming Ren; Wenyi Wei
Journal:  Trends Biochem Sci       Date:  2018-10-01       Impact factor: 13.807

5.  The critical role of CD4+ T cells in PD-1 blockade against MHC-II-expressing tumors such as classic Hodgkin lymphoma.

Authors:  Joji Nagasaki; Yosuke Togashi; Takeaki Sugawara; Makiko Itami; Nobuhiko Yamauchi; Junichiro Yuda; Masato Sugano; Yuuki Ohara; Yosuke Minami; Hirohisa Nakamae; Masayuki Hino; Masahiro Takeuchi; Hiroyoshi Nishikawa
Journal:  Blood Adv       Date:  2020-09-08

6.  Nivolumab in relapsed/refractory Hodgkin lymphoma: towards a new treatment strategy?

Authors:  Emanuele Cencini; Monica Bocchia; Alberto Fabbri
Journal:  Am J Blood Res       Date:  2021-06-15

Review 7.  Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Front Oncol       Date:  2018-03-07       Impact factor: 6.244

Review 8.  The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.

Authors:  Ines Garces de Los Fayos Alonso; Huan-Chang Liang; Suzanne D Turner; Sabine Lagger; Olaf Merkel; Lukas Kenner
Journal:  Cancers (Basel)       Date:  2018-03-28       Impact factor: 6.639

9.  Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis.

Authors:  Ben Wang; Zhujie Ran; Mengmeng Liu; Yunsheng Ou
Journal:  Front Immunol       Date:  2019-07-15       Impact factor: 7.561

10.  Spatial signatures identify immune escape via PD-1 as a defining feature of T-cell/histiocyte-rich large B-cell lymphoma.

Authors:  Gabriel K Griffin; Jason L Weirather; Margaretha G M Roemer; Mikel Lipschitz; Alyssa Kelley; Pei-Hsuan Chen; Daniel Gusenleitner; Erin Jeter; Christine Pak; Evisa Gjini; Bjoern Chapuy; Michael H Rosenthal; Jie Xu; Benjamin J Chen; Aliyah R Sohani; Scott B Lovitch; Jeremy S Abramson; Jeffrey J Ishizuka; Austin I Kim; Caron A Jacobson; Ann S LaCasce; Christopher D Fletcher; Donna Neuberg; Gordon J Freeman; F Stephen Hodi; Kyle Wright; Azra H Ligon; Eric D Jacobsen; Philippe Armand; Margaret A Shipp; Scott J Rodig
Journal:  Blood       Date:  2021-03-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.